Taysha Gene Therapies (NASDAQ:TSHA) Price Target Raised to $11.00

Taysha Gene Therapies (NASDAQ:TSHA) had its price objective upped by Canaccord Genuity Group from $9.00 to $11.00 in a report issued on Tuesday,Benzinga reports. They currently have a buy rating on the stock.

A number of other research analysts have also recently issued reports on TSHA. Citigroup reiterated an “outperform” rating on shares of Taysha Gene Therapies in a research report on Thursday, May 29th. JMP Securities lifted their target price on Taysha Gene Therapies from $5.00 to $6.00 and gave the company a “market outperform” rating in a research report on Thursday, May 29th. Needham & Company LLC reiterated a “buy” rating and issued a $8.00 target price (up previously from $6.00) on shares of Taysha Gene Therapies in a research report on Monday. Chardan Capital lifted their target price on Taysha Gene Therapies from $7.00 to $9.00 and gave the company a “buy” rating in a research report on Thursday, May 29th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a research report on Monday, April 28th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Taysha Gene Therapies presently has a consensus rating of “Buy” and an average price target of $7.57.

Taysha Gene Therapies Stock Down 0.4%

TSHA stock opened at $2.78 on Tuesday. The company has a market cap of $596.76 million, a PE ratio of 4.41 and a beta of 0.90. The business has a 50-day simple moving average of $1.96 and a 200 day simple moving average of $1.91. Taysha Gene Therapies has a 52 week low of $1.05 and a 52 week high of $4.32. The company has a quick ratio of 5.51, a current ratio of 5.51 and a debt-to-equity ratio of 0.48.

Taysha Gene Therapies (NASDAQ:TSHA) last released its earnings results on Thursday, May 15th. The company reported ($0.08) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.08). Taysha Gene Therapies had a negative return on equity of 106.36% and a negative net margin of 229.67%. The firm had revenue of $2.30 million for the quarter, compared to analysts’ expectations of $1.48 million. During the same quarter in the previous year, the business posted ($0.10) earnings per share. Sell-side analysts anticipate that Taysha Gene Therapies will post -0.35 EPS for the current fiscal year.

Insider Transactions at Taysha Gene Therapies

In other news, major shareholder Paul B. Manning purchased 750,000 shares of Taysha Gene Therapies stock in a transaction dated Friday, May 30th. The shares were bought at an average cost of $2.75 per share, for a total transaction of $2,062,500.00. Following the completion of the acquisition, the insider now owns 2,841,704 shares in the company, valued at approximately $7,814,686. This trade represents a 35.86% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 2.70% of the company’s stock.

Institutional Trading of Taysha Gene Therapies

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Granahan Investment Management LLC lifted its stake in shares of Taysha Gene Therapies by 0.3% in the first quarter. Granahan Investment Management LLC now owns 1,640,793 shares of the company’s stock worth $2,281,000 after acquiring an additional 4,412 shares during the period. Hsbc Holdings PLC lifted its stake in shares of Taysha Gene Therapies by 65.6% in the fourth quarter. Hsbc Holdings PLC now owns 20,391 shares of the company’s stock worth $36,000 after acquiring an additional 8,076 shares during the period. Virtus ETF Advisers LLC lifted its stake in shares of Taysha Gene Therapies by 43.0% in the fourth quarter. Virtus ETF Advisers LLC now owns 31,597 shares of the company’s stock worth $55,000 after acquiring an additional 9,494 shares during the period. Geode Capital Management LLC lifted its stake in shares of Taysha Gene Therapies by 0.3% in the fourth quarter. Geode Capital Management LLC now owns 3,572,349 shares of the company’s stock worth $6,182,000 after acquiring an additional 9,591 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its stake in shares of Taysha Gene Therapies by 2.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 474,257 shares of the company’s stock worth $820,000 after acquiring an additional 11,390 shares during the period. 77.70% of the stock is currently owned by institutional investors.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.